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Abstract
Objectives: Surgical resection represents the main curative treatment for giant hepatic haemangioma
(GHH). The aim of this study was to compare the respective outcomes of hepatic enucleation (HE) and
hepatic resection (HR) for GHH.
Methods: Giant hepatic haemangioma was defined as haemangioma of 5–15 cm in size. A prospec-
tively maintained database consisting of a series of consecutive patients who underwent HE or HR of
GHH from January 2004 to December 2013 was analysed.
Results: Hepatic enucleation was performed in 386 (52.9%) patients and HR in 344 (47.1%) of a final
cohort of 730 patients. The median size of GHH was similar in the HR and HE groups (9.8 and
10.6 cm, respectively; P = 0.752). The HE group had a shorter median operative time (150 min versus
240 min; P = 0.034), shorter median hospital stay (5.7 days versus 8.6 days; P < 0.001), lower median
blood loss (400 ml versus 860 ml; P < 0.001), and fewer complications (17.6% versus 28.2%;
P < 0.001) than the HR group. Quality of life scores in both the HR and HE groups significantly
improved compared with preoperative levels and were similar to those found in healthy Chinese
individuals following surgery, confirming the efficacy of both treatments.
Conclusions: Hepatic enucleation was associated with favourable operative outcomes compared with
HR and is a safe and effective alternative to partial hepatectomy for GHH.
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Introduction
Hepatic haemangioma is the most frequent benign hepatic
tumour. It shows a female predominance in all age groups and
is increasingly found incidentally on abdominal ultrasonogra-
phy or computed tomography examinations.1–3 The over-
whelming majority of haemangiomas are asymptomatic and do
not require intervention. However, large haemangiomas can
produce a variety of symptoms, including abdominal, shoulder
and back pain, nausea, vomiting, jaundice, abdominal disten-
sion and dyspnoea. In addition, thrombocytopoenia, fever and
compression of adjacent structures, rupture and consumptive
coagulopathy (Kasabach–Merritt syndrome) have been
reported.4–6
Indications for surgery include severe progressive symptoms,
increase in size, inability to exclude malignancy, and a high
risk for hepatic injury and complications.7,8 Size alone is not,
however, an indication for surgery.9
Giant hepatic haemangioma (GHH) is defined as haemangi-
oma of ≥5 cm in size. Treatment modalities for symptomatic
GHH, such as medical therapies, arterial ligation, transcatheter
arterial embolization (TAE), radiofrequency ablation and liver
transplantation, have been applied with variable success.10–14
Surgical resection or transplantation remain the only consis-
tently curative methods of treatment for symptomatic GHH.
Hepatic enucleation (HE) and hepatic resection (HR) have both
been described; however, it is unclear which of these treatments
is superior. The aim of this study was to compare the outcomes
of patients undergoing HE or HR for the management of GHH
with the purpose of identifying an optimal treatment strategy.
Materials and methods
The study protocol conformed to the ethical guidelines of the
1975 Declaration of Helsinki and was approved by the Clinical
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Trial Ethics Committee of West China Hospital. Written
informed consent was obtained from each participant before
surgery. A prospective database comprising demographic infor-
mation, perioperative parameters and complications in all
patients with hepatic haemangioma who underwent surgical
intervention has been maintained since 2004. Inclusion criteria
for this study required patients to demonstrate hepatic
haemangioma of 5–15 cm in diameter, along with indications
for surgery that included the presence of progressive symp-
toms, increasing size, inability to exclude malignancy, or com-
plications following a period of observation. Exclusion criteria
denied the participation of patients with cirrhosis or another
significant comorbidity. Patients who refused to participate
were not included. Patients with GHH of >15 cm in size were
excluded because the preferred treatment option in these cases
was TAE followed by HE and thus their inclusion would have
biased the comparison of HE with HR.
The choice of surgical technique was left to the individual
surgeon. A total of nine surgeons contributed patients to the
study. For both HE and HR, the surgical procedure was per-
formed using a Chevron incision. Surgery was performed
under low central venous pressure anaesthesia. Intermittent
vascular inflow control was used as required. Transection of
the liver parenchyma was undertaken using a water-jet dissec-
tor and/or an ultrasonic dissector (Cavitron Ultrasonic Surgical
Aspirator; Tyco Healthcare Group, Mansfield, MA, USA). In
patients treated with HR, the aim was to achieve a tumour-free
resection margin of 0.5–1.0 cm as estimated by visual inspec-
tion and to avoid peritumoural vessels. Hepatic enucleation
was performed under vascular inflow control with the tumour
dissected from normal hepatic parenchyma by meticulous dis-
section of the surgical plane, ligating or clipping feeding vessels
as exposed.15 All excised specimens were submitted for histo-
pathological analysis. Massive haemorrhage was defined as
intraoperative blood loss of >1000 ml. Bile leak was defined as
external drainage or intra-abdominal collection of fluid charac-
terized as bile. Perioperative morbidity and mortality included
complications or death occurring during the hospital stay or
within the 30 days after the operation. Perioperative morbid-
ity was categorized according to the Clavien–Dindo system of
classification.16
The 36-item Short-Form Health Survey (SF-36) question-
naire was administered to all patients in both groups before
surgery and at 1, 3 and 6 months after surgery. The SF-36 is a
well-validated questionnaire that measures eight areas of
health: physical functioning; role–physical; role–emotional;
bodily pain; vitality; mental health; social functioning, and gen-
eral health.17 The summary score is derived from a total of
scores on all items, with the worst score being 0 (poor health)
and the best score being 100 (good health). Scores on the
SF-36 were compared between the HE and HR groups and
with established scores of healthy persons in China.18
Statistical analysis
Discrete variables were assessed for statistical significance using
the chi-squared test. Continuous data are expressed as the
median (range). Two-tailed Mann–Whitney U-tests and log
rank tests were used to compare outcomes between the HE
and HR groups as appropriate. A P-value of ≤0.05 was consid-
ered to indicate statistical significance. All analyses were
performed using SPSS for Windows Version 16.0 (SPSS, Inc.,
Chicago, IL, USA).
Results
A total of 2865 patients in whom a diagnosis of haemangioma
of the liver was documented between January 2004 and
December 2013 were identified. Of these, 1003 (35.0%)
patients were identified with GHH.
Of the 1003 patients, 200 (19.9%) were identified as having
GHH of >15 cm in largest diameter and were therefore
excluded. Seventy-three patients were deceased at the time of
the survey and thus were excluded from analysis because the
available data were insufficient. A total of 730 (25.5% of the
full cohort) patients were included in the current study. Of
these, 386 patients (52.9%) underwent HE and 344 patients
(47.1%) underwent HR. The clinical characteristics of all
included patients are summarized in Table 1.
Operative data and morbidity for the two groups are shown in
Tables 2 and 3, respectively. Overall, 352 (91.2%) of the 386
patients in the HE group and 308 (89.5%) of the 344 patients in
the HE group completed the SF-36 assessment at their 1-, 3- and
6-month follow-ups. Preoperative SF-36 scores did not differ
significantly between the HE and HR groups on any of the eight
domains (Table 4), but were significantly lower in all eight
domains than those recorded for healthy Chinese individuals. At
6 months after surgery, SF-36 scores in both the HE and HR
groups were comparable with those in Chinese normal individuals.
Discussion
Haemangioma is the most common neoplasm of the liver,
affecting 3–20% of the general population.19 Most hepatic
haemangiomas are small and stable, and are usually managed
expectantly in the absence of symptoms or complications. The
natural history of hepatic haemangioma remains unclear.
Although spontaneous rupture of GHH has been reported in
the literature, it is rare and prophylactic resection is not
recommended.13,20,21 Schnelldorfer et al.22 demonstrated that
non-operative management of GHH of the liver is safe, even in
patients with extremely large hepatic haemangiomas. Therefore,
although resection or enucleation of haemangiomas can be
performed with low morbidity, operative intervention should
be recommended only in patients with symptoms that are suf-
ficiently severe to affect lifestyle and to justify operative risk. In
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Table 1 Clinical characteristics of patients undergoing hepatic resection (HR) or hepatic enucleation (HE) for giant hepatic haemangioma
Clinical characteristics HE group (n = 386) HR group (n = 344) P-value
Gender, male, n (%) 224 (58.0%) 205 (59.6%) 0.764
Age, years, median (range) 45 (20–70) 46 (21–68) 0.455
ASA status (I/II/III), n 267/111/8 245/92/7 0.327
Surgical indications, n (%)
Symptomatic 222 (57.5%) 197 (57.3%) 0.234
Progressive increase in size 89 (23.1%) 80 (23.3%) 0.542
Haemangioma related complications 42 (10.9%) 37 (10.8%) 0.324
Uncertain diagnosis 24 (6.2%) 22 (6.4%) 0.265
Other 9 (2.3%) 8 (2.3%) 0.321
Tumour location (segment), n
I 3 5 0.132
II, III 44 39 0.228
IV 98 88 0.176
V, VI 166 147 0.253
VII, VIII 75 65 0.154
Largest tumour size, cm, median (range) 9.8 (1.5–5.7) 10.6 (1.8–4.4) 0.752
Solitary haemangioma, n (%) 304 (78.8%) 276 (80.2%) 0.541
ASA, American Society of Anesthesiologists.
Table 2 Operative data for patients with giant hepatic haemangioma undergoing hepatic enucleation (HE) or hepatic resection (HR)
Parameters HE group (n = 386) HR group (n = 344) P-value
Operative time, min, median (range) 150 (30–275) 240 (50–400) <0.001
Blood loss, ml, median (range) 400 (150–600) 860 (300–1250) <0.001
Units of auto-transfusion, units, median (range) 1.5 (0.5–2.0) 3.5 (1.5–6.0) <0.001
Specimen weight, g, median (range) 385.5 (45–125) 355.7 (40–130) 0.037
Hospital stay, days, median (range) 5.7 (6–11) 8.6 (7–20) <0.001
Table 3 Postoperative morbidity and mortality in patients undergoing hepatic enucleation (HE) or hepatic resection (HR) for giant hepatic
haemangioma
Parameters HE group (n = 386) n (%) HR group (n = 344) n (%) P-value
Patients with complications 68 (17.6) 97 (28.2) <0.001
Major complication (≥Grade III) 57 (14.8) 70 (20.3) 0.065
Bile leak (Grade III) 33 (8.5) 55 (15.9) 0.002
Acute hepatic failure (Grade IV) 3 (0.8) 4 (1.2) 0.603
Ascites (Grade I) 34 (8.8) 51 (14.8) 0.010
Perihepatic abscess (Grade III) 7 (1.8) 6 (1.7) 0.473
Postoperative haemorrhage (Grade IV) 5 (1.3) 6 (1.7) 0.620
Reoperation 3 (0.8) 5 (1.5) 0.391
Mortality 0 0 1.000
Complications are graded according to Dindo et al.16 Grade I complications require variation without necessitating operative or medicinal treat-
ment. Grade II complications need medicinal therapy. Grade III complications need operative, endoscopic or radiologic assistance. Grade IV
complications are life-threatening additional complications which include central nervous system, solitary body organ malfunction, and multi-
organ malfunction necessitating intensive care unit treatment. Grade V complications involve the death of the affected individual. In the existing
analysis, complications of Grades I and II are categorized as minor and those of Grades III–V are considered to be major complications.
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the present series, all patients submitted to surgery had signifi-
cantly reduced SF-36 scores in all domains in comparison with
scores in healthy Chinese individuals (Table 4), which indicates
that this cohort represents a well-selected patient group.
In this large series, patients were managed by either HE or
HR. Although the technique selected was left to the discretion
of the individual surgeon, there was no evidence that the
groups were fundamentally different in terms of preoperative
risk factors or extent of disease. Perioperatively, HE was associ-
ated with significant reductions in blood loss, operative time,
hospital stay and complications. Not unexpectedly, there were
no differences in postoperative quality of life (QoL) scores
between the two techniques and by 6 months QoL scores in
both groups had significantly improved compared with
preoperative levels and were similar to those found in healthy
Chinese individuals, confirming the efficacy of both treatments.
The results of the current study demonstrate that HE was
associated with significantly less operative blood loss, a shorter
hospital stay, fewer complications and shorter operative time
compared with HR in patients with GHH.
Major intraoperative haemorrhage can be a significant prob-
lem during surgical treatment for GHH. Severe blood loss is a
contributing factor to the occurrence of complications.23
Vascular inflow control and low central venous pressure anaes-
thesia are standard procedures employed to reduce blood loss
during liver resection. In the current series, vascular inflow
control was used in both groups. When bleeding occurs during
HE, it can be controlled by extrahepatic ligation of the right or
left hepatic artery. After the relevant hepatic artery has been
ligated, there is a gradual reduction in the size of the haemang-
ioma, which may be augmented by gentle pressure. However,
for segment IV lesions, more selective dissection controlling
the relevant feeding vessels may be necessary.
Hanazaki et al.9 previously reported that patients with
tumours of ≥10 cm in size required a mean of 15 units of blood,
5.3-fold more than that required for patients with tumours of
<10 cm, and experienced higher rates of postoperative complica-
tions and mortality because of the risk for haemorrhage and the
need for abundant intraoperative transfusions. These results may
explain why the incidence of morbidity was higher in the HR
group (28.2%) than in the HE group (17.6%), although no oper-
ative mortality occurred in either group.
Conclusions
Liver enucleation combined with inflow occlusion was associ-
ated with favourable operative outcomes compared with
conventional hepatectomy. Therefore, enucleation should be
considered a viable and preferable option in the treatment of
patients with GHH.
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